Lanzhou Foci Pharmaceutical Co Ltd (002644) — Net Asset Quality Index
Lanzhou Foci Pharmaceutical Co Ltd (002644) has a Net Asset Quality Index of 73.1% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.52 Billion minus total liabilities of CN¥678.01 Million yields net assets of CN¥1.85 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 002644 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Lanzhou Foci Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2007–2024)
This chart shows how Lanzhou Foci Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the index stands at 73.1%, representing net assets of CN¥1.85 Billion against total assets of CN¥2.52 Billion CNY. Explore Lanzhou Foci Pharmaceutical Co Ltd cash conversion from operations to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Lanzhou Foci Pharmaceutical Co Ltd (2007–2024)
The table below presents the year-by-year Net Asset Quality Index for Lanzhou Foci Pharmaceutical Co Ltd from 2007 to 2024, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Lanzhou Foci Pharmaceutical Co Ltd market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 73.5% | CN¥1.81 Billion | CN¥2.47 Billion | CN¥654.81 Million | ▲ +3.5 pp |
| 2023 | 70.0% | CN¥1.77 Billion | CN¥2.53 Billion | CN¥759.67 Million | ▲ +2.9 pp |
| 2022 | 67.0% | CN¥1.73 Billion | CN¥2.59 Billion | CN¥852.60 Million | ▼ -2.2 pp |
| 2021 | 69.2% | CN¥1.63 Billion | CN¥2.35 Billion | CN¥724.59 Million | ▲ +2.7 pp |
| 2020 | 66.5% | CN¥1.59 Billion | CN¥2.39 Billion | CN¥800.08 Million | ▲ +3.7 pp |
| 2019 | 62.8% | CN¥1.51 Billion | CN¥2.40 Billion | CN¥893.78 Million | ▲ +5.7 pp |
| 2018 | 57.1% | CN¥1.44 Billion | CN¥2.52 Billion | CN¥1.08 Billion | ▼ -0.8 pp |
| 2017 | 57.8% | CN¥1.36 Billion | CN¥2.35 Billion | CN¥990.68 Million | ▼ -5.5 pp |
| 2016 | 63.4% | CN¥1.29 Billion | CN¥2.04 Billion | CN¥746.13 Million | ▼ -27.2 pp |
| 2015 | 90.5% | CN¥1.23 Billion | CN¥1.36 Billion | CN¥128.77 Million | ▲ +20.3 pp |
| 2014 | 70.2% | CN¥735.22 Million | CN¥1.05 Billion | CN¥311.40 Million | ▼ -7.6 pp |
| 2013 | 77.9% | CN¥703.37 Million | CN¥903.08 Million | CN¥199.70 Million | ▼ -4.2 pp |
| 2012 | 82.1% | CN¥675.53 Million | CN¥822.91 Million | CN¥147.38 Million | ▲ +3.9 pp |
| 2011 | 78.2% | CN¥648.08 Million | CN¥829.23 Million | CN¥181.14 Million | ▲ +6.6 pp |
| 2010 | 71.6% | CN¥326.46 Million | CN¥456.16 Million | CN¥129.70 Million | ▲ +11.6 pp |
| 2009 | 59.9% | CN¥252.96 Million | CN¥422.05 Million | CN¥169.09 Million | ▲ +5.8 pp |
| 2008 | 54.1% | CN¥216.81 Million | CN¥400.52 Million | CN¥183.70 Million | ▼ -0.1 pp |
| 2007 | 54.2% | CN¥195.20 Million | CN¥359.92 Million | CN¥164.72 Million | — |